bullish
Moderna (MRNA US): Blowout Q1 Results; Maintained Guidance; Visibility Beyond COVID
335 Views05 May 2022 17:02
SUMMARY
- Moderna Inc (MRNA US) reported strong Q1 results, with revenue and EPS beating consensus by 33% and 65%, respectively. The company reiterated 2022 Covid vaccine sales guidance of $21 billion.
- With the pandemic likely to evolve into and endemic phase with a more seasonal sales pattern, Moderna is advancing its vaccine and therapeutic pipeline beyond COVID.
- Beginning in the fall of 2022, Moderna could see three respiratory commercial launches over the next two to three years. Moderna is looking for potential M&A opportunities across the globe.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Moderna (MRNA US): Q3 Result Misses Expectations; Guidance Slashed As COVID Vax Shipment Deferred04 Nov 2022
- Moderna (MRNA US): Better-Than-Expected Q2 Result; Guidance Reiterated; $3B Share Buyback Announced04 Aug 2022
- Data Mining Technical Publications to Rank the Innovators in RNA Therapeutics12 Jul 2022
- Moderna (MRNA US): Blowout Q1 Results; Maintained Guidance; Visibility Beyond COVID05 May 2022
- Strong Quarterly Results And New $3B Share Repurchase Plan28 Feb 2022
- Is It Time For Moderna To Boost Share Buyback And Start Paying Dividends?20 Jan 2022
- Moderna (MRNA US): To Cash in on Omicron Fear04 Dec 2021
x